Vericel (VCEL) Misses Q1 EPS by 3c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
May 5, 2021 7:00 AM EDTFirst Quarter Total Net Revenue Increased 30% to $34.6 Million
Full-Year 2021 Revenue Guidance Raised to $165-$168 Million
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2021.
First Quarter 2021 Financial Highlights
Total net revenue increased 30% to $34.6... More